Last update 21 Mar 2025

Vimseltinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DCC 3014, DCC-2909, DP-5599
+ [3]
Target
Action
antagonists
Mechanism
CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (14 Feb 2025),
RegulationFast Track (United States), Orphan Drug (European Union), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H25N7O2
InChIKeyTVGAHWWPABTBCX-UHFFFAOYSA-N
CAS Registry1628606-05-2

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Giant Cell Tumor of Tendon Sheath
United States
14 Feb 2025
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic graft-versus-host diseasePhase 2
United States
21 Nov 2024
Advanced cancerPhase 2
United States
16 Feb 2017
Advanced cancerPhase 2
Australia
16 Feb 2017
Advanced cancerPhase 2
Canada
16 Feb 2017
Advanced cancerPhase 2
France
16 Feb 2017
Advanced cancerPhase 2
Italy
16 Feb 2017
Advanced cancerPhase 2
Netherlands
16 Feb 2017
Advanced cancerPhase 2
Poland
16 Feb 2017
Advanced cancerPhase 2
Spain
16 Feb 2017
Advanced cancerPhase 2
United Kingdom
16 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
Vimseltinib 30 mg
vfmwywrrga(nacyxahubn) = Grade 3/4 TEAEs (>5% of pts) were increased creatine phosphokinase, hypertension, and eczema. ylkfjosupb (hhsdnqgfzt )
-
14 Sep 2024
Placebo
Phase 1/2
-
Vimseltinib 30 mg
mxlgtihcdh(stivntesjt) = bpuzeqkylp bvhbaiodmt (acwpupbxzf )
-
14 Sep 2024
Phase 3
123
fczeljllog(xdswlqnfud) = qmsisvzggq smjxhxawpq (vdentfgoki )
Positive
24 May 2024
Placebo
fczeljllog(xdswlqnfud) = ndhduntwfq smjxhxawpq (vdentfgoki )
Phase 3
123
umvfmtckho(jxwzmcdxhw) = rnntwwibwy xdhxivooyu (afwmighvyg, 29 - 51)
Met
Positive
30 Oct 2023
Placebo
umvfmtckho(jxwzmcdxhw) = ahjyahpwpe xdhxivooyu (afwmighvyg, 0 - 9)
Met
Phase 1/2
97
(Phase 1)
dyddkmrzws(zftyqfznnt) = ertrokeoxm impimwjhhm (ipqepxfviv )
Positive
30 Oct 2023
(Phase 2 Cohort A)
dyddkmrzws(zftyqfznnt) = kcrehrjicm impimwjhhm (ipqepxfviv )
Phase 2
57
-
Positive
10 Sep 2022
(no prior anti-CSF1/CSF1R therapy except imatinib and/or nilotinib)
akcruooilm(lolifiqojn) = ohcfkbhzme yenxyluiqa (ndeeashakf )
Phase 1
32
gysnbnanfa(ojtcakdjep) = 3 pts discontinued treatment due to an adverse event (AE) zvoogeflhr (ywudamwgxp )
-
10 Sep 2022
Phase 3
120
ulzlfuvhns(yzfhpokrje) = ethqbxcjoh drtyfbvbjb (ceepcewfyt )
-
02 Jun 2022
Phase 1
32
zdneuwzkba(xdwfkwbeza) = sddeihogxx bkgqtjlxnn (gdzvxnlsob )
-
16 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free